Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan;130(2):57-77.
doi: 10.1042/CS20150469.

The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment

Massimo Volpe  1 , Marino Carnovali  2 , Vittoria Mastromarino  3
Affiliations
Review

The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment

Massimo Volpe et al. Clin Sci (Lond). 2016 Jan.

Abstract

After its discovery in the early 1980s, the natriuretic peptide (NP) system has been extensively characterized and its potential influence in the development and progression of heart failure (HF) has been investigated. HF is a syndrome characterized by the activation of different neurohormonal systems, predominantly the renin-angiotensin (Ang)-aldosterone system (RAAS) and the sympathetic nervous system (SNS), but also the NP system. Pharmacological interventions have been developed to counteract the neuroendocrine dysregulation, through the down modulation of RAAS with ACE (Ang-converting enzyme) inhibitors, ARBs (Ang receptor blockers) and mineralcorticoid antagonists and of SNS with β-blockers. In the last years, growing attention has been paid to the NP system. In the present review, we have summarized the current knowledge on the NP system, focusing on its role in HF and we provide an overview of the pharmacological attempts to modulate NP in HF: from the negative results of the study with neprilysin (NEP) inhibitors, alone or associated with an ACE inhibitor and vasopeptidase inhibitors, to the most recently and extremely encouraging results obtained with the new pharmacological class of Ang receptor and NEP inhibitor, currently defined ARNI (Ang receptor NEP inhibitor). Indeed, this new class of drugs to manage HF, supported by the recent results and a vast clinical development programme, may prompt a conceptual shift in the treatment of HF, moving from the inhibition of RAAS and SNS to a more integrated target to rebalance neurohormonal dysregulation in HF.

Keywords: LCZ696 (sacubitril/valsartan); bradykinin; heart failure; natriuretic peptides; neprilysin; neuroendocrine syndrome.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Tissue expression of NPs, proteolytic activation processing from pre-prohormones to mature and biologically active peptides
Figure 2
Figure 2. Natriuretic peptide-binding receptors, intracellular signalling and degradation processes
Abbreviations: GC-A: guanylate cyclase type A; GC-B: guanylate cyclase type B.
Figure 3
Figure 3. Effects of NEP activity on NP, RAAS and bradykinin system (A) and consequences of NEP inhibition (B), vasopeptidase inhibition (C) and ARNI (D) on the same systems
Abbreviation: BK: bradykinin.
Figure 4
Figure 4. Current therapeutic approaches for HF and the novel role of ARNI
Figure 5
Figure 5. Ang NEP inhibition with LCZ696 doubles beneficial effect on cardiovascular death of current inhibitors of the renin–Ang system
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Francis G.S., Benedict C., Johnstone D.E., Kirlin P.C., Nicklas J., Liang C.S., Kubo S.H., Rudin-Toretsky E., Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD) Circulation. 1990;82:1724–1729. doi: 10.1161/01.CIR.82.5.1724. - DOI - PubMed
    1. Francis G.S., McDonald K.M., Cohn J.N. Neurohormonal activation in preclinical heart failure: remodeling and the potential for intervention. Circulation. 1993;87(Suppl. IV):IV-90–96. - PubMed
    1. Benedict C.R., Shelton B., Johnstone D.E., Francis G., Greenberg B., Konstam M., Probstfield J.L., Yusuf S. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation. 1996;94:690–697. doi: 10.1161/01.CIR.94.4.690. - DOI - PubMed
    1. Volpe M., Tritto C., De Luca N., Mele A.F., Lembo G., Rubattu S., Romano M., De Campora P., Enea I., Ricciardelli B., et al. Failure of atrial natriuretic factor to increase with saline load in patients with dilated cardiomyopathy and mild heart failure. J. Clin. Invest. 1991;88:1481–1489. doi: 10.1172/JCI115458. - DOI - PMC - PubMed
    1. Magri P., Rao M.A., Cangianiello S., Bellizzi V., Russo R., Mele A.F., Andreucci M., Memoli B., De Nicola L., Volpe M. Early impairment of renal hemodynamic reserve in patients with asymptomatic heart failure is restored by angiotensin II antagonism. Circulation. 1998;98:2849–2854. doi: 10.1161/01.CIR.98.25.2849. - DOI - PubMed

Publication types